Rhythm Biosciences Limited (ASX:RHY)
Australia · Delayed Price · Currency is AUD 0.0910
-0.0050 (-5.21%)
Sep 1, 2025, 4:10 PM AEST
Rhythm Biosciences Revenue
In the fiscal year ending June 30, 2025, Rhythm Biosciences had annual revenue of 3.33M AUD with 96.80% growth. Rhythm Biosciences had revenue of 3.17M in the half year ending December 31, 2024, with 16.37% growth.
Revenue
3.33M
Revenue Growth
+90.90%
P/S Ratio
7.77
Revenue / Employee
n/a
Employees
n/a
Market Cap
25.85M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 3.33M | 1.64M | 96.80% |
| Jun 30, 2024 | 1.69M | -1.41M | -45.41% |
| Jun 30, 2023 | 3.10M | 668.44K | 27.54% |
| Jun 30, 2022 | 2.43M | 1.32M | 118.98% |
| Jun 30, 2021 | 1.11M | 1.01M | 1,008.51% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CSL Limited | 23.73B |
| Pro Medicus | 212.98M |
| Cochlear | 2.34B |
| Sonic Healthcare | 9.65B |
| Ramsay Health Care | 17.85B |
| Telix Pharmaceuticals | 1.01B |
| Ansell | 3.06B |
| Mesoblast | 26.23M |